Comparison of effect of preoperative dienogest and gonadotropin-releasing hormone agonist administration on laparoscopic cystectomy for ovarian endometriomas

Rie Ozaki, Jun Kumakiri, Makoto Jinushi, Shinichiro Ikuma, Keisuke Murakami, Yu Kawasaki, Mari Kitade
Archives of gynecology and obstetrics · 2020 · vol. 302(4) , pp. 969–976 · doi:10.1007/s00404-020-05691-3 · PMID:32661756 · W3040979859
article OA: closed CC0 ⤵ 8 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex View on PubMed
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

This study compared preoperative dienogest and GnRH agonist in 70 women undergoing laparoscopic cystectomy for endometriomas, finding dienogest improved symptoms and reduced hot flashes with higher rates of breast pain and metrorrhagia.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This randomized study compared preoperative dienogest (DNG) for 4 months versus low-dose sustained-release goserelin acetate for 4 months in 70 patients scheduled for laparoscopic cystectomy for ovarian endometriomas, assessing preoperative symptom measures (NRS endometriosis pain and Kupperman index), hormonal therapy adverse events, and surgical outcomes (total duration, blood loss) plus 12-month endometrioma recurrence. After hormonal therapy, both NRS and KI were significantly lower in the DNG group than the GnRH agonist group, and hot flashes were less frequent with DNG, but breast pain and metrorrhagia were more frequent; total surgical duration and blood loss did not differ, and no recurrence was observed in either group at 12 months. A key limitation explicitly noted in the abstract-level reporting is the relatively short follow-up for recurrence assessment (12 months) and the focus on symptom/surgical outcomes rather than broader endpoints like ovarian reserve. This paper is centrally about endometriosis — it evaluates how preoperative dienogest compares with a GnRH agonist to improve symptoms and surgical outcomes for ovarian endometriomas treated with laparoscopic cystectomy.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral, Hormonal Cystectomy Endometriosis Endometriosis Gonadotropin-Releasing Hormone Hormone Antagonists Laparoscopy Nandrolone Adolescent Adult Contraceptives, Oral, Hormonal Contraceptives, Oral, Hormonal Cystectomy Endometriosis Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Hormone Antagonists Hormone Antagonists Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (32)

Cited by (8)

Source provenance

europepmc
last seen: 2026-07-01T06:12:12.862213+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:21:53.586419+00:00
License: CC0 · commercial use OK